Innovation Never Stops

Organoids by Southwest : OXSW

Innovation Never Stop

organoids by SOuthwest : oxsw

Bringing Organoid Innovation to the Next Level

OXSW, the U.S. subsidiary of OrganoidScience, is dedicated to advancing organoid-based pipeline development.

Based in Texas, our team leverages advanced organoid platforms to identify, validate, and accelerate next-generation therapies.

With a strong foundation in innovation and collaboration, OXSW is committed to shaping the future of biomedical research and therapeutic development.

OUR 4 Business model

New Pipeline Development

Regenerative Medicine

Technology Innovation

Precision Medicine

Why the U.S.?

The U.S. offers a supportive regulatory and innovation environment, ideal for advancing organoid and cell therapy technologies. By entering the U.S., we aim to fully realize the global potential of breakthroughs that began in Korea.

Mission

Accelerating healthcare innovation by combining Korean and U.S. breakthroughs to transform early discoveries into impactful therapies.

Technology

Harnessing automation, robotics, and AI to make organoid research reproducible, efficient, and scalable.

Collaboration

Partnering with global and local leaders to expand pipelines and fast-track clinical translation.

Vision

Turning organoid breakthroughs into real-world therapies, driving global innovation from the U.S. hub.

Join our

innovative

journey

Name

Phone

Comment

SEND

Confirm